Blake Moore: “This is a brainchild of Trump's first administration.”

“If a treatment can meet the FDA's burden of proof of safe and effective and other requirements for breakthrough designation, there's no reason Medicare shouldn't be able to provide temporary medical coverage while CMS completes its review for permanent coverage. And This is a brainchild of Trump's first administration. We've talked about this. We all agree in principle about this. It's difficult to move in some cases. But can you update this committee on your efforts to implement a policy like this through any type of executive rulemaking?” (02:29–02:32)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.